Treatment of Sepsis with Thrombin-Activatable Fibrinolysis Inhibitor (TAFI)

Technology:
2001-002-002

Inventors:
Dr. Fletcher Taylor and Lazlo Bajzar

Invention Description:
The OMRF invention provide a method and pharmaceutical compositions for treatment of sepsis and other disorders characterized by dysfunctional endothelium. The technology consisting essentially of an effective amount of thrombin-activatable fibrinolysis inhibitor (TAFI) is administered alone or in combination with other treatments, such as administration of activated protein C (APC). The effective amount of TAFI is administered to the patient, prior to, or during sepsis, in an amount effective to promote fibrinolysis.

Market Application:
Worldwide, more than a million people die from thrombosis each year. Severe sepsis affects about 750,000 people in the U.S. every year, and the cost of care is approximately 17 Billion.

Features, Benefits, and Advantages:
OMRF Invention offers a different approach to stop the life threatening complications of infection and sepsis.

Intellectual Property:
US Patent 6,838,432

Stage of Development
Proof of concept studies completed. We are currently seeking industry partners to collaborate with us (in the form of research collaboration, licensing etc.) to develop and commercialize this technology.